|
|
||||||||
Lexington, Kentucky
ABSTRACT
51Chromium albumin, prepared by a standardized method in a commercial radiopharmaceutical laboratory, has been characterized and found to be altered from the parent material and, to a degree, biologically inhomogeneous. It has, however, been shown to be a suitable agent for the clinical evaluation of plasma protein loss into the gastrointestinal tract and to have advantages over other methods and radioisotopes tracers for this purpose. In tracer doses, it does not constitute a radiologic health hazard.
FOOTNOTES
1 From the Departments of Pediatrics and Therapeutic Radiology, University of Kentucky School of Medicine.
2 Supported in part by USPHS Research Grant No. AM-08059 from the National Institute of Health.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |